124 related articles for article (PubMed ID: 10533322)
1. Low-dose GnRH agonist therapy for the management of endometriosis.
Uemura T; Shirasu K; Katagiri N; Asukai K; Suzuki T; Suzuki N; Osada H; Hiroshi M
J Obstet Gynaecol Res; 1999 Oct; 25(5):295-301. PubMed ID: 10533322
[TBL] [Abstract][Full Text] [Related]
2. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis.
Surrey ES; Gambone JC; Lu JK; Judd HL
Fertil Steril; 1990 Apr; 53(4):620-6. PubMed ID: 2108056
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
Schindler AE; Bühler K; Mettler L; Fuchs U; Cirkel U; Ochs H; Schweppe KW; Koch R
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
[TBL] [Abstract][Full Text] [Related]
4. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
Ohtsuka S; Terakawa N; Shimizu I; Sakata M; Mizutani T; Miyake A; Tanizawa O; Aono T
Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
[TBL] [Abstract][Full Text] [Related]
5. Buserelin acetate implants in the treatment of pain in endometriosis.
Choktanasiri W; Rojanasakul A
J Med Assoc Thai; 2001 May; 84(5):656-60. PubMed ID: 11560214
[TBL] [Abstract][Full Text] [Related]
6. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
Biberoglu K; Gursoy R; Yildiz A
Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
[TBL] [Abstract][Full Text] [Related]
7. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis.
Uemura T; Mohri J; Osada H; Suzuki N; Katagiri N; Minaguchi H
Fertil Steril; 1994 Aug; 62(2):246-50. PubMed ID: 8034067
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
10. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
Nencioni T; Penotti M; Barbieri-Carones M; Ortolani S; Trevisan C; Polvani F
Gynecol Endocrinol; 1991 Mar; 5(1):49-56. PubMed ID: 1910246
[TBL] [Abstract][Full Text] [Related]
12. [Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].
Masaoka K; Kitazawa M; Watanabe H; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):729-36. PubMed ID: 2504848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
14. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
15. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
Donnez J; Nisolle-Pochet M; Clerckx-Braun F; Sandow J; Casanas-Roux F
Fertil Steril; 1989 Jul; 52(1):27-30. PubMed ID: 2501110
[TBL] [Abstract][Full Text] [Related]
16. Hormone treatment related bone mineral content changes in Japanese women with endometriosis.
Fukushima M; Shindo M; Sato K
Asia Oceania J Obstet Gynaecol; 1993 Sep; 19(3):299-307. PubMed ID: 8250765
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
Akira S; Mine K; Kuwabara Y; Takeshita T
Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
[TBL] [Abstract][Full Text] [Related]
18. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.
Minaguchi H; Uemura T; Shirasu K
Prog Clin Biol Res; 1986; 225():211-25. PubMed ID: 3097667
[No Abstract] [Full Text] [Related]
19. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
Lemay A; Maheux R; Jean C; Faure N
Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
[No Abstract] [Full Text] [Related]
20. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol.
Tummon IS; Ali A; Pepping ME; Radwanska E; Binor Z; Dmowski WP
Fertil Steril; 1988 May; 49(5):792-6. PubMed ID: 3129312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
